BriaCell Therapeutics Files Definitive Proxy Statement

TL;DR

BriaCell filed its proxy statement, shareholders vote soon.

AI Summary

BriaCell Therapeutics Corp. filed a definitive proxy statement (DEF 14A) on December 17, 2024. This filing is related to the company's annual meeting and is not a preliminary statement. The company was formerly known as Ansell Capital Corp. until a name change on June 13, 2014.

Why It Matters

This filing provides shareholders with essential information regarding the upcoming annual meeting, including voting procedures and company proposals, allowing them to make informed decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.

Key Players & Entities

• BriaCell Therapeutics Corp. (company) — Registrant
• Ansell Capital Corp. (company) — Former company name
• December 17, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $1.235 billion — ing growth company if we have more than $1.235 billion in annual revenues as of the end of a f
• $1.0 billion — ; SEC ”) or if we issue more than $1.0 billion of non-convertible debt over a three-ye

Filing Documents

• formdef14a.htm (DEF 14A) — 802KB
• formdef14a_001.jpg (GRAPHIC) — 5KB
• formdef14a_002.jpg (GRAPHIC) — 45KB
• formdef14a_003.jpg (GRAPHIC) — 245KB
• formdef14a_004.jpg (GRAPHIC) — 236KB
• formdef14a_005.jpg (GRAPHIC) — 232KB
• formdef14a_006.jpg (GRAPHIC) — 174KB
• 0001493152-24-050399.txt ( ) — 2095KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy (Amendment No.__) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to § 240.14a-12 BRIACELL THERAPEUTICS CORP. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply) No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. BRIACELL THERAPEUTICS CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS OF BRIACELL THERAPEUTICS CORP. TO BE HELD ON THURSDAY, JANUARY 23, 2025 AT 10:00 A.M. (EASTERN TIME) DECEMBER 13, 2024 This proxy statement is dated December 13, 2024, and is first being made available to shareholders on December 17, 2024 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15th Street West Vancouver, BC V7T 2X1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (the “Notice”) The annual general meeting (the “ Meeting ”) of holders (“ Shareholders ”) of common shares (“ Common Shares ”) of BriaCell Therapeutics Corp., a British Columbia corporation (the “ Company ”), will be held on Thursday, January 23, 2025, beginning at 10:00 a.m. (Eastern Time), at the offices of Bennett Jones LLP at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The following matters will be considered at the Meeting: 1. The receipt of the audited financial statements of the Company for the financial years ended July 2024 and 2023, together with the auditor’s reports thereon; 2. The appointment of MNP LLP as auditors for the Company and the authorization of the board of directors of the Company (the “ Board ” or the “ Board of Directors ”) to fix the auditors’ remuneration and terms of engagement; 3. The election of the directors for the forthcoming year from the nominees proposed by the Board; and 4. The transaction of such other business as may properly come before the Meeting or any adjournment(s) or postponement(s) thereof. This Notice is accompanied by the: (1) proxy statement; (2) the accompanying proxy card (“ Proxy Card ”); and (3) the Company’s Annual Report on Form 10-K for the year ended July 31, 2024 (including the audited annual consolidated financial statements of the Company for the fiscal year ended July 31, 2024, together with the notes thereto, and the independent auditor’s report thereon and the related management’s discussion and analysis) (collectively, the “ Proxy Materials ”). The Company is not sending the Proxy Materials to registered Shareholders or non-registered Shareholders using notice-and-access delivery procedures defined under NI 54-101 and National Instrument 51-102 – Continuous Disclosure Obligations . The record date for the determination of Shareholders of the Company entitled to receive notice of and to vote at the Meeting or any adjournment(s) or postponement(s) thereof is December 9, 2024 (the “ Record Date ”). Shareholders of the Company whose names have been entered in the register of Shareholders of the Company at the close of business on the Record Date will be entitled to receive notice of and to vote at the Meeting or any adjournment(s) or postponement(s) thereof. I-1 A Shareholder of the Company may attend the Meeting or may be represented by proxy. Registered Shareholders of the Company who are unable to attend the Meeting or any adjournment(s) or postponement(s) thereof are requested to date, sign and return the accompanying Proxy Card for use at the Meeting or any adjournment(s) or postponement(s) thereof and deposit it with the Company’s transfer agent, Computershare Investor Services Inc., Proxy Department 8 th Floor, 100 University Avenue, Toronto, Ontario M5J 2Y1. Your proxy or voting instructions must be received in each case no later than 10:00 a.m. (Eastern Time) on January 21, 2025 or, if the Meeting is adjourned, at least 48 hours (excluding Saturdays, Sundays and statutory holidays in the Province of British Columbia) before the beginning of any adjournment(s) or postponement(s) to the Meeting. We encourage Shareholders currently planning to participate in the Meeting to submit their votes or Proxy Card in advance so that their votes will be counted in the event of technical difficulties. If you are a non-registered shareholder of the Company and receive these materials through your broker or another intermediary, please complete and return the

View Full Filing

View this DEF 14A filing on SEC EDGAR